Transcatheter aortic valve replacement for severe aortic stenosis can improve long-term survival of nonagenarians as compared to an age- and sex-matched general population.


Journal

Journal of cardiology
ISSN: 1876-4738
Titre abrégé: J Cardiol
Pays: Netherlands
ID NLM: 8804703

Informations de publication

Date de publication:
02 2020
Historique:
received: 19 05 2019
revised: 26 06 2019
accepted: 18 07 2019
pubmed: 3 9 2019
medline: 1 1 2021
entrez: 3 9 2019
Statut: ppublish

Résumé

Nonagenarians are at increased risk for morbidity and mortality after transcatheter aortic valve replacement (TAVR) based solely on their age. The aim of our study was to evaluate survival of nonagenarians with severe aortic valve stenosis (AS) after TAVR as compared to an age- and sex-matched general population. From 2009 to 2017, 1052 consecutive patients ≥80 years scheduled for TAVR were included. Patients were divided into three groups depending on their age at the time of the procedure: 80-84 (Group 1), 85-89 (Group 2) and ≥90 years (Group 3). Survival of patients treated with TAVR was compared to the life expectancy of an age- and sex-matched cohort in the general population. Nonagenarians were more likely to experience major access-site complications than their younger counterparts (7.6% Group 1 vs. 10.1% Group 2 vs. 17.6% Group 3, p=0.016). One-year mortality in nonagenarians was higher as compared to the general population (27.8% vs. 20.0%). After two years, the mortality curves between the TAVR patients and the general population converged (39.2% vs. 37.5%) and were lower after five years. During the observation period of five years, carefully selected nonagenarians treated with TAVR had at least the same mortality rate as an age- and sex-matched general population after two years despite procedure-associated complications. The negative prognostic impact of the severe AS was completely eliminated by TAVR.

Sections du résumé

BACKGROUND
Nonagenarians are at increased risk for morbidity and mortality after transcatheter aortic valve replacement (TAVR) based solely on their age. The aim of our study was to evaluate survival of nonagenarians with severe aortic valve stenosis (AS) after TAVR as compared to an age- and sex-matched general population.
METHODS
From 2009 to 2017, 1052 consecutive patients ≥80 years scheduled for TAVR were included. Patients were divided into three groups depending on their age at the time of the procedure: 80-84 (Group 1), 85-89 (Group 2) and ≥90 years (Group 3). Survival of patients treated with TAVR was compared to the life expectancy of an age- and sex-matched cohort in the general population.
RESULTS
Nonagenarians were more likely to experience major access-site complications than their younger counterparts (7.6% Group 1 vs. 10.1% Group 2 vs. 17.6% Group 3, p=0.016). One-year mortality in nonagenarians was higher as compared to the general population (27.8% vs. 20.0%). After two years, the mortality curves between the TAVR patients and the general population converged (39.2% vs. 37.5%) and were lower after five years.
CONCLUSIONS
During the observation period of five years, carefully selected nonagenarians treated with TAVR had at least the same mortality rate as an age- and sex-matched general population after two years despite procedure-associated complications. The negative prognostic impact of the severe AS was completely eliminated by TAVR.

Identifiants

pubmed: 31474498
pii: S0914-5087(19)30240-0
doi: 10.1016/j.jjcc.2019.07.014
pii:
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

134-139

Informations de copyright

Copyright © 2019 Japanese College of Cardiology. Published by Elsevier Ltd. All rights reserved.

Auteurs

Sebastian Barth (S)

Cardiovascular Center Bad Neustadt/Saale, Department of Cardiology, Bad Neustadt/Saale, Germany. Electronic address: sebastian.barth@campus-nes.de.

Martina B Hautmann (MB)

Cardiovascular Center Bad Neustadt/Saale, Department of Cardiology, Bad Neustadt/Saale, Germany.

Wilko Reents (W)

Cardiovascular Center Bad Neustadt/Saale, Department Cardiac Surgery, Bad Neustadt/Saale, Germany.

Michael Zacher (M)

Cardiovascular Center Bad Neustadt/Saale, Department Cardiac Surgery, Bad Neustadt/Saale, Germany.

Daniel P Griese (DP)

Department of Cardiology, Sana Klinikum Hameln-Pyrmont, Hameln, Germany.

Sebastian Kerber (S)

Cardiovascular Center Bad Neustadt/Saale, Department of Cardiology, Bad Neustadt/Saale, Germany.

Anno Diegeler (A)

Cardiovascular Center Bad Neustadt/Saale, Department Cardiac Surgery, Bad Neustadt/Saale, Germany.

Karsten Hamm (K)

Cardiovascular Center Bad Neustadt/Saale, Department of Cardiology, Bad Neustadt/Saale, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH